Osimertinib(奥希替尼)泰瑞沙的药物禁忌说明,Osimertinib(Osimertinib)禁忌为：1、对奥希替尼或药物中的任何成分过敏的患者禁用；2、孕妇患者禁用；3、哺乳期妇女禁用。

Title: Osimertinib (Tagrisso) Drug Contraindications: A Comprehensive Overview

Introduction:

Osimertinib, marketed under the trade name Tagrisso, is a targeted therapy used in the treatment of specific forms of lung cancer. While Osimertinib has shown efficacy in prolonged survival rates and improved outcomes in patients with certain genetic mutations, it is essential to be aware of the drug's contraindications. This article aims to provide a comprehensive overview of the contraindications associated with Osimertinib usage.

1. Contraindication in Allergic Reactions:

Allergic reactions are a primary contraindication for the use of Osimertinib. Patients with a known hypersensitivity or previous allergic reactions to Osimertinib or any of its components should avoid its use. Such individuals may develop severe allergic reactions, including rash, itching, swelling, dizziness, or breathing difficulties, which may require immediate medical attention.

2. Contraindication during Pregnancy and Breastfeeding:

Osimertinib is classified as Pregnancy Category D. It is contraindicated for use in pregnant women as it can potentially cause harm to the developing fetus. Studies in animals have demonstrated fetal abnormalities and adverse effects on pregnancy outcomes. Therefore, women of childbearing potential should use appropriate contraceptive methods during treatment with Osimertinib.

Furthermore, Osimertinib can pass into breast milk and may harm the nursing infant. Breastfeeding should be avoided during Osimertinib therapy and for at least 2 weeks after the final dose.

3. Contraindication with Severe Hepatic Impairment:

Patients with pre-existing severe hepatic impairment should not use Osimertinib. The drug is metabolized primarily in the liver, and severe hepatic impairment can significantly alter its pharmacokinetics and increase the risk of adverse events. Alternative treatment options should be considered in such cases.

4. Contraindication with Concomitant Strong CYP3A Inducers:

Osimertinib is primarily metabolized by the cytochrome P450 enzyme CYP3A. The concomitant use of strong CYP3A inducers may significantly decrease the plasma concentrations of Osimertinib, reducing its efficacy. Therefore, co-administration of Osimertinib with strong CYP3A inducers, such as rifampicin, carbamazepine, phenytoin, and St. John's Wort, should be avoided. If alternative treatment options are not feasible, closely monitor the patient for adequate Osimertinib efficacy.

5. Contraindication with QT Prolongation:

Osimertinib may cause QT interval prolongation, which can lead to an increased risk of serious arrhythmias. Consequently, it is contraindicated in patients with a history of or predisposition to QT interval prolongation. Physicians should conduct a thorough assessment of the patient's cardiovascular health and consider alternative treatment options if needed.

Conclusion:

Osimertinib (Tagrisso) is an important targeted therapy for certain forms of lung cancer. However, it is crucial to be aware of the drug's contraindications to ensure safe and effective treatment. Allergic reactions, pregnancy and breastfeeding, severe hepatic impairment, concomitant use with strong CYP3A inducers, and QT prolongation are important factors to consider when prescribing or administering Osimertinib. Patients and healthcare professionals should communicate closely and proactively to make informed decisions regarding the use of Osimertinib, taking into account the patient's specific medical history and needs.